Interdict

Executive Summary

Interdict is a private, early-stage biotechnology company leveraging a highly innovative small molecule platform to address historically undruggable targets across oncology, rare diseases, neurodegeneration, and autoimmunity. Founded in 2022 and headquartered in Cambridge, USA, the company aims to expand the druggable proteome by employing advanced computational chemistry and structure-based design. Despite being at a nascent stage with no disclosed funding or pipeline details, Interdict's platform holds broad therapeutic potential and addresses significant unmet medical needs. The company's ability to validate its technology in preclinical models and attract strategic partnerships will be critical near-term value drivers. Given the early-stage nature and lack of public data, conviction is moderate but could increase with upcoming milestones.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round60% success
• Q1 2027Lead Program Preclinical Data Release (e.g., in oncology)50% success
• Q2 2027Collaboration or Licensing Deal with Established Pharma30% success